To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Advancing ATMPs for orphan diseases: redefining the roles of pharmaceutical companies and academia
Reimbursement routes and past practices for advanced therapy medicinal products in the Netherlands
Publication: Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe
Article in BJCP: ‘EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells’
Rapport ‘Geneesmiddelen voor Geavanceerde Therapie (ATMP’s) in Nederland: Veldverkenning, Knelpuntanalyse en Activiteitenkaart’ (in Dutch)
Article in Journal of Clinical Oncology: ‘Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed’
Review article in Frontiers in Immunology: ‘Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations’
Review article in IOTECH: ‘Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit’